VERAXA Biotech shows tumor regression with single‑dose BiTAC‑ADC in preclinical study
VERAXA Biotech AG presented first in‑vivo proof‑of‑concept data for its BiTAC‑ADC platform at the World ADC Congress in San Diego on October 13, 2026. A single 3 mg/kg dose caused strong tumor regression in a xenograft breast‑cancer model, while body weight remained stable. The results illustrate the platform’s tumor‑specific activation and differentiated safety profile compared with conventional ADCs.
Why it matters
The company says the data validate the safety and efficacy of BiTAC‑ADCs, which could make the platform more attractive for future partnerships and clinical development. Investors may view the milestone as de‑risking the technology ahead of upcoming clinical trials.
Key facts
- 1The in‑vivo data were presented at the 17th World ADC Congress in San Diego, CA, on October 13, 2026. finanznachrichten.de
- 2A single dose of 3 mg/kg of the BiTAC‑ADC induced strong tumor regression in a xenograft breast‑cancer model. finanznachrichten.de
- 3No decrease in body weight was observed in the treated animals. finanznachrichten.de
- 4The BiTAC‑ADC platform uses two separate antibody components that must co‑localize in the tumor to activate the cytotoxic payload. finanznachrichten.de
- 5Chief Scientific Officer Christoph Erkel highlighted the safety benefits of the BiTAC‑ADC concept. finanznachrichten.de
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.